An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer

CompletedOBSERVATIONAL

Enrollment

1,937

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

April 24, 2025

Study Completion Date

April 24, 2025

Conditions

Breast Cancer

Interventions

OTHER

ribociclib

This is an observational study. There is no treatment allocation. The decision to initiate ribociclib was based solely on clinical judgement.

Trial Locations (1)

Novartis investigative site, München